Additional file 1 of FMRP ligand circZNF609 destabilizes RAC1 mRNA to reduce metastasis in acral melanoma and cutaneous melanoma

Additional file 1: Fig. S1. Verification of highly invasive HMY-1 cell sublines. a The growth pattern of HMY-1 and highly invasive HMY-1 cell sublines. b and c In vitro Transwell assay to verify the different metastatic potential between HMY-1 and highly invasive HMY-1 sublines. d The expression of circZNF609 in HMY-1 and highly invasive HMY-1 cell sublines. Fig. S2. Abundant circRNAs in human melanomas. a and b The abundant circRNAs in 3 cutaneous melanoma cell lines (a) and 4 normal skin tissues(b). c circRNAs riched in melanoma cell lines and normal skin tissues. d Selection of circRNAs that may truly participate in the progression of melanoma. Fig. S3. circZNF609 knockdown and overexpression efficiency in melanoma. a-c circZNF609 knockdown efficiency (left) and overexpression efficiency (right) in HMY-1 (a), A2058 (b) and A875 (c). Fig. S4. Cell migratory and invasive capabilities were assessed after modulation of circZNF609. a and b circZNF609 overexpression in 2 acral melanoma cells (a) and 2 cutaneous melanoma cells (b) suppressed cell migration and invasion. c Cell migratory capability was assessed by wound healing assay after knocking down or overexpressing circZNF609 in 2 melanoma cells. Fig. S5. The expression and cellular distribution of FMRP were assessed after circZNF609 modulation. a and b circZNF609 modulation in melanoma cells did not alter the expression (a) or cellular distribution (b) of FMRP. Fig. S6. RAC1 expression and survival analysis in cancers. a The high expression of RAC1 in numerous cancers. b The Kaplan-Meier survival analysis of RAC1 in numerous cancers. Fig. S7. Unprocessed figures of western blot assays. Fig. S8. Unprocessed figures of western blot assays.